Providing Scholarships, Class Reunion Assistance, and More...

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial Can-Fite BioPharma Ltd.

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial Can-Fite BioPharma Ltd. , a biotechnology business advancing a pipeline of proprietary small molecule drugs that address inflammatory and tumor diseases, today announced that it offers dosed the first patient in a Phase II trial for the treating hepatocellular carcinoma , the most common form of liver tumor http://sustanon300.net . The Stage II randomized, double-blind, placebo controlled trial is to be executed in the U.S., Israel and Europe with an estimated 78 patients to be enrolled. CF 102 has been evaluated for efficacy and security as a second-series treatment for advanced HCC in topics with Child-Pugh B who failed Nexavar as a first line treatment.